

**Manuscript version: Author's Accepted Manuscript**

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

**Persistent WRAP URL:**

<http://wrap.warwick.ac.uk/110837>

**How to cite:**

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

**Publisher's statement:**

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk).

1 **It is Time to Give Social Research a Voice to Tackle AMR**

2 **Marco J HAENSSGEN** <sup>a, b, c, d, f, \*</sup>

3 **Nutcha CHAROENBOON** <sup>d</sup>

4 **Yuzana KHINE ZAW** <sup>d, e</sup>

5 <sup>a.</sup> Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine,  
6 University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK

7 <sup>b.</sup> CABDyN Complexity Centre, Saïd Business School, University of Oxford, Park End Street, Oxford  
8 OX1 1HP, Oxford, UK

9 <sup>c.</sup> Green Templeton College, 43 Woodstock Road, Oxford OX2 6HG, UK

10 <sup>d.</sup> Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol  
11 University, 3/F, 60th Anniversary Chulalongkornrajavidyalaya Building, 420/6 Rajvithi Road, Bangkok, Thailand

12 <sup>e.</sup> Department of Global Health and Development, London School of Hygiene & Tropical Medicine,  
13 London, UK

14 <sup>f.</sup> email: marco.haenssger@ndm.ox.ac.uk, phone: +44 (0) 7771805068

15 <sup>\*</sup> Corresponding author

16 **WORD COUNT**

17 746

18 **It is Time to Give Social Research a Voice to Tackle AMR**

19 Sir,

20 We have noted the recent review by Zellweger *et al.* with great interest.<sup>1</sup> The authors highlight trends  
21 and challenges in antimicrobial resistance (AMR) in Southeast Asia and – encouragingly for us as  
22 social researchers – point out the need for social science research in a field that is dominated by the  
23 medical and biological sciences. We, too, call for more social research to understand and address  
24 antimicrobial use and resistance, but this will require a stronger voice for social scientists.

25 Considering that antimicrobial use and resistance “have a large behavioural component,”<sup>1</sup> the near-  
26 absence of social sciences research in AMR prevents comprehensive understanding and effective  
27 policy responses. Take for instance something as seemingly simple as the language to communicate  
28 the problem of antimicrobial resistance to the general population. Mendelson *et al.* alluded in a recent  
29 comment to the lacking popular awareness of “antimicrobial resistance” and the problematic  
30 translation of the term into other languages.<sup>2</sup> In our own social research in rural northern Thailand  
31 (Chiang Rai; a mostly rural district with 1.3 million inhabitants),<sup>3</sup> we have also come across varied  
32 expressions of “antibiotics.” For example, rather than “wonder drugs,” antibiotics are often referred to  
33 as “anti-inflammatory medicine” (“ยาแก้อักเสบ” or “yah kae ak seb”), which links to local descriptions of  
34 illnesses as being caused by “inflammations” of the body (e.g. in the case of a sore throat). Moreover,  
35 some local ethnic groups in Chiang Rai (e.g. Akha) may not have an equivalent of the Thai term in  
36 their mother tongue and rather refer to antibiotics as the “medicine that relieves the pain,” and yet other  
37 people would not actively distinguish between antibiotics and other kinds of medicine.<sup>i</sup> The literal

---

<sup>i</sup> These are not the only examples, and our informants also had a wide range of notions and descriptions for other medicines ranging from brand names (e.g. Tiffy) via generic descriptions (fever reliever) to descriptions of appearance (“the white pill”).

38 translation of “antibiotic” (“ยาปฏิชีวนะ” or “yah pa ti chee wa na”) is a technical term with Pali roots (akin  
39 to Latin) that is hardly used or understood in rural Chiang Rai. Even seemingly unambiguous  
40 expressions like “drug resistance” (“ดื้อยา” or “due yah”)—literally translated into being “stubborn to  
41 [the effects of] medicine”—are being interpreted by non-native speakers or people without active  
42 conceptions of antibiotic resistance as meaning “stubborn to take medicine.” Language is therefore not  
43 merely a means to overcome “irrational behaviour” but it also reflects more fundamentally how people  
44 think about medicine and illness. We first need to understand and address such deeper-rooted local  
45 conceptions and behaviours involving antimicrobial use. AMR information campaigns referring for  
46 example to “antibiotics,” “bacteria,” or “viruses” could otherwise be fruitless or have unforeseen  
47 behavioural repercussions.<sup>4</sup>

48 In addition, the common policy emphasis on education and “awareness raising” to address behavioural  
49 aspects of AMR<sup>5-8</sup> assumes that “irrational” choices are the main driver behind problematic  
50 antimicrobial-related behaviour (e.g. over- or under-use of antibiotics), but not all medicine  
51 consumption is the result of active choice. Social, economic, and health system constraints may drive  
52 people into behaviours where they may be more likely to access antimicrobials—knowingly or  
53 unknowingly. Not only do we need qualitative as well as quantitative social research to understand the  
54 nature and extent of such structural constraints of antimicrobial use (note that the social sciences are  
55 neither a homogeneous field nor synonymous to qualitative research).<sup>ii</sup> In terms of AMR policy, these  
56 broader determinants of behaviour also require us to think beyond medical and health policy solutions.

---

<sup>ii</sup> The various social science disciplines could make different contributions to the field of AMR. For example, social anthropologists and historians might situate current antibiotic usage patterns in a broader social and historical context in order to understand their meaning and origin, microeconomists might consider the role of individual incentives in healthcare choices, or development studies researchers might examine the distribution of power from the micro to the macro level to understand pitfalls, failures, and inequities associated with AMR-related interventions.

57 Might for instance sick leave, social protection policies, access to financial services like loans and  
58 savings accounts, or more efficient public transport alleviate some of the constraints that shape the  
59 antimicrobial use among groups who lack access to medical supervision?

60 Social scientists do not hold a monopoly on social research questions, and the appreciation of social  
61 phenomena by medical AMR researchers is laudable indeed. Yet, the continuing absence of social  
62 research is a threat to understanding and addressing the social dimensions of AMR more  
63 comprehensively and effectively.

#### 64 **Transparency declarations**

65 None to declare.

#### 66 **References**

- 67 **1.** Zellweger RM, Carrique-Mas J, Limmathurotsakul D *et al.* A current perspective on antimicrobial  
68 resistance in Southeast Asia. *J Antimicrob Chemother* 2017; **72**: 2963-72.
- 69 **2.** Mendelson M, Balasegaram M, Jinks T *et al.* Antibiotic resistance has a language problem. *Nature*  
70 2017; **545**: 23-5.
- 71 **3.** National Statistical Office. The 2010 population and housing census. Bangkok: Ministry of  
72 Information and Communication Technology, 2011.
- 73 **4.** Lambert H. The rhetoric of resistance. *Social science research for understanding drug resistant*  
74 *infections*. AMR Social Science Champion, 2016. [https://amrchamp.blogs.ilrt.org/2016/09/21/the-](https://amrchamp.blogs.ilrt.org/2016/09/21/the-rhetoric-of-resistance/)  
75 [rhetoric-of-resistance/](https://amrchamp.blogs.ilrt.org/2016/09/21/the-rhetoric-of-resistance/)
- 76 **5.** The Review on Antimicrobial Resistance. *Tackling drug-resistant infections globally: final report*  
77 *and recommendations*. London: The UK Prime Minister, 2016.
- 78 **6.** Gelband H, Miller-Petrie M, Pant S *et al.* *State of the world's antibiotics, 2015*. Washington, DC:  
79 Center for Disease Dynamics, Economics & Policy, 2015.



- 80 7. Department of Health. *UK five year antimicrobial resistance strategy: 2013 to 2018*. London:  
81 Department of Health, 2013.
- 82 8. WHO. *Global action plan on antimicrobial resistance*. Geneva: World Health Organization, 2015.

